Competition for the generic drug Betmiga (Mirabegron), an overactive bladder treatment, is intensifying in the outpatient prescription market.

According to the drug market research agency UBIST on the 20th, the Mirabegron market scale in the first quarter reached ₩18.3 billion. It increased by 9% compared to ₩16.7 billion in the same period last year (1st quarter of 2020).

It is an analysis that the addition of generics has contributed to the expansion of the market size.
Hanmi Pharm and Chong Kun Dang released Mirabek and Selebeta consecutively in June and July of last year through the avoidance of Betmiga patents. The sales of both items totaled ₩1.4 billion in